Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2020

View Archived Issues

FDA approves IND to treat COVID-19 patients with stem cells

HMPL-306 enters phase I study for hematological malignancies in China

NP strategy selectively targets brain microvasculature

MPI-8 reduces thrombosis without increased bleeding in vivo

Discovery and preclinical evaluation of novel direct FXIa inhibitor, ONO-1600586

Structural study gives insight into plaque formation

QF-036, a new HIV maturation inhibitor, shows no toxicity in single or repeated dose studies in rats

JAK1 inhibitor CJ-14939 may be a potential adjuvant for NSCLC patients with erlotinib resistance

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent Nav1.8 channel blockers

New STING agonists identified at Shanghai Institute of Materia Medica

Breztri Aerosphere approved in U.S. for the maintenance treatment of COPD

Biomea Fusion discovers menin (MEN1)/MLL interaction inhibitors

New mutation in FGB gene found in afibrinogenemia

Beijing Boe Technology Development, Boe Technology Group present EPCAM-targeting agents

Genentech discovers Ire1-alpha inhibitors

FDA allows initiation of clinical trials for desidustat in chemotherapy-induced anemia

Tecartus wins accelerated approval from FDA for relapsed or refractory mantle cell lymphoma

Tumor regression reported in first patients treated with TC-210 in phase I/II study

FDA maintains clinical hold on IGNITE DMD study of SGT-001

Moderna announces phase III study initiation with mRNA-1273 for COVID-19

4D Molecular studies gene therapy 4D-110 in phase I for choroideremia

Fluorine-18 labeling extends half-life of mGluR2 ligand for PET imaging in the brain

Vertex begins phase II trial of VX-864 in PiZZ genotype AAT deficiency

Lung Therapeutics initiates phase II trial of LTI-01 for pleural effusion

Alector begins phase III trial of AL-001 in frontotemporal dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...